US4320137A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Derivatives of perhydro-aza-heterocycles
Assignee: Novartis Corp
•
Filing: 1980-09-28
•
Granted: 1982-03-16
•
Expires: 2000-09-28
Abstract
Abstract The present invention provides new derivatives of perhydro-aza-heterocycles of the formula <IMAGE> (I) in which X is the oxo radical or hydrogen and the radical OR1, in which R1 is hydrogen or a substituted or unsubstituted aliphatic hydrocarbon radical, a substituted or unsubstituted araliphatic hydrocarbon radical or a substituted or unsubstituted aromatic hydrocarbon radical or an acyl radical, R2 is hydrogen or a substituted or unsubstituted aliphatic hydrocarbon radical, Y is oxygen or sulphur, n1 and n2 each are values of 1 to 3, n1+n2 being at most four, and Ar is a substituted or unsubstituted aromatic hydrocarbon radical, and the acid addition salts, in particular the pharmaceutically acceptable acid addition salts thereof. These new substances possess valuable pharmacological properties, in particular antidepressant activity, and can be used for the treatment of mental depressions. Specific embodiments are trans- and cis-3-hydroxy-4-(3,4-dimethyl-phenoxy)-piperidine, trans- und cis-3-hydroxy-4-(2,3-dimethyl-phenoxy)-piperidine, their 1-methyl derivatives and the pharmaceutically acceptable salts of these substances.
Inventors
- 👤 Romeo Paioni
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 13:43
CPC Classifications
C; C07; C07D; C07D491/00; C07D491/02; C07D491/04; A; A61; A61P; A61P25/00; A61P25/18; A61P25/24; A61P25/26; C07D207/00; C07D207/02; C07D207/04; C07D207/10; C07D207/12; C07D207/18; C07D207/22; C07D207/24; C07D211/00; C07D211/04; C07D211/06; C07D211/36; C07D211/40; C07D211/42; C07D211/44; C07D211/46; C07D211/54; C07D211/68; C07D211/72; C07D211/74; C07D223/00; C07D223/02; C07D223/06; C07D223/08
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
106 words
A compound of the formula ##STR9## wherein X is hydrogen and the radical OR 1 , in which R 1 is hydrogen, lower alkyl or an acyl group --C(═O)--R, in which R is lower alkyl, R 2 is hydrogen, lower alkyl, lower alkenyl or lower alkinyl, Ar is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl, which are unsubstituted or mono- or disubstituted in an aromatic ring, at most two substituents being selected from lower alkyl, lower alkoxy and halogen, and at most one substituent being selected from trifluoromethyl, carbamoyl, nitro and cyano, Y is oxygen, n 1 and n 2 are each one, or an acid addition salt thereof.
Claim 2
Dependent Claim
106 words
A compound of the formula ##STR9## wherein X is hydrogen and the radical OR 1 , in which R 1 is hydrogen, lower alkyl or an acyl group --C(═O)--R, in which R is lower alkyl, R 2 is hydrogen, lower alkyl, lower alkenyl or lower alkinyl, Ar is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl, which are unsubstituted or mono- or disubstituted in an aromatic ring, at most two substituents being selected from lower alkyl, lower alkoxy and halogen, and at most one substituent being selected from trifluoromethyl, carbamoyl, nitro and cyano, Y is oxygen, n 1 and n 2 are each one, or an acid addition salt thereof.
Claim 3
Dependent Claim
95 words
A compound according to claim 1, in which X is hydrogen and the radical OR 1 , in which R 1 is hydrogen, lower alkyl or an acyl group --C(═O)--R, in which R is lower alkyl, R 2 is hydrogen, lower alkyl or propargyl, Ar is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl, and phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy or halogen, or substituted by trifluoromethyl, said substituents being identical or different from one another, Y is oxygen, n 1 and n 2 are each one, or an acid addition salt thereof.
Claim 4
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-phenoxy-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(4-carbamoyl-phenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(4-methoxy-phenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 7
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(1-naphthyloxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(2-methyl-phenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 9
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(3,4-dimethyl-phenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 10
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-acetoxy-4-(3,4-dimethyl-phenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 11
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(3-chlorophenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 12
Dependent Claim
17 words
A compound according to claim 1, which is trans-3-hydroxy-4-(3,5-dimethyl-phenoxy)-pyrrolidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 13
Dependent Claim
137 words
A pharmaceutical composition for the treatment of mental depression comprising a therapeutically effective amount of a compound of the formula ##STR10## wherein X is hydrogen and the radical OR 1 , in which R 1 is hydrogen, lower alkyl or an acyl group --C(═O)--R, in which R is lower alkyl, R 2 is hydrogen, lower alkyl, lower alkenyl or lower alkinyl, Ar is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl which are unsubstituted or mono- or disubstituted in an aromatic ring, at most two substituents being selected from lower alkyl, lower alkoxy, and halogen, and at most one substituent being selected from trifluoromethyl, carbamoyl, nitro and cyano, said substituents being identical or different from one another, Y is oxygen, n 1 and n 2 are each one, or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutical excipient.
Claim 14
Dependent Claim
137 words
A pharmaceutical composition for the treatment of mental depression comprising a therapeutically effective amount of a compound of the formula ##STR10## wherein X is hydrogen and the radical OR 1 , in which R 1 is hydrogen, lower alkyl or an acyl group --C(═O)--R, in which R is lower alkyl, R 2 is hydrogen, lower alkyl, lower alkenyl or lower alkinyl, Ar is phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl which are unsubstituted or mono- or disubstituted in an aromatic ring, at most two substituents being selected from lower alkyl, lower alkoxy, and halogen, and at most one substituent being selected from trifluoromethyl, carbamoyl, nitro and cyano, said substituents being identical or different from one another, Y is oxygen, n 1 and n 2 are each one, or a pharmaceutically acceptable acid addition salt thereof together with a pharmaceutical excipient.
Claim 15
Dependent Claim
108 words
A pharmaceutical composition according to claim 12, wherein a therapeutically effective amount of a compound of formula I given in claim 12, in which X is hydrogen, lower alkyl or an acyl group --C(═O)--R, in which R is lower alkyl, R 2 is hydrogen, lower alkyl or propargyl, Ar is Phenyl, naphthyl or 5,6,7,8-tetrahydronaphthyl, and phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy or halogen, or substituted by trifluoromethyl, said substituents being identical or different from one another, Y is oxygen, n 1 and n 2 are each one, or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutical excipient, is present.
Claim 16
Dependent Claim
29 words
A pharmaceutical composition according to claim 12, wherein a therapeutically effective amount of 3-hydroxy-4-(3,4-dimethyl-phenoxy)-pyrrolidine or of a pharmaceutically acceptable acid salt thereof, together with a pharmaceutical excipient, is present.
Claim 17
Dependent Claim
30 words
A pharmaceutical composition according to claim 12, wherein a therapeutically effective amount of 3-hydroxy-4-(1-naphthyloxy)-pyrrolidine or of a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutical excipient, is present.
Claim 18
Dependent Claim
49 words
A method for the treatment of mental depression in a warm-blooded animal comprising enteral or parenteral administration to said animal of a therapeautically, effective amount of a compound according to claim 1, having the formula 1 defined in claim 1, or of a pharmaceutically acceptable acid addition salt thereof.
References Cited (Backward Citations)
US3381013A
Cited
US3446897A
Cited
US3627766A
Cited
US3823151A
Cited
CH511874A
Cited
US3577432A
Cited
DE1964515A1
Cited
US3961959A
Cited
US4160837A
Cited
US4246269A
Cited
DE3000625A1
Cited
DE3000624A1
Cited
DE3000623A1
Cited
GB2040933A
Cited
US4251541A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-03-15 | 1985-09-14 | 1986-03-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-03-15 | 1989-09-14 | 1990-03-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-03-15 | 1993-09-14 | 1994-03-16 | $7700.00 | Window Closed / Lapsed |